gsk

GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease

The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) brings together GSK’s expertise in the science of the immune system, AI and clinical development with Cambridge’s complementary ...
gsk

ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with ...

CROWN is the first large, phase IIIb international trial to evaluate the investigational use of long-acting Cabenuva versus daily oral therapy in people with a history of antiretroviral treatment and ...
gsk

Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 A new oral option may ...
gsk

For media and investors only

Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year.
gsk

VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain

SARS-CoV-2 spike protein (B.1.351 strain) vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the European Union Results show the SARS-CoV-2 ...
gsk

GSK plc commences share buyback programme

GSK plc ("GSK") today announces the commencement of its share buyback programme (the “Programme”), as announced in its 2024 full year results announcement published on 5 February 2025 (the “FY24 ...
gsk

GSK provides update on belrestotug development programme

GSK plc (LSE/NYSE: GSK), with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug, an anti-TIGIT monoclonal antibody. The decision is ...
gsk

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an ...
gsk

For media and investors only

Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition Approved in the US for use in adults and ...
gsk

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts ...

Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) Vaccines sales £2.3 billion (+8%) ...
gsk

GSK mother and baby homes information service

We have established an enhanced information service for former residents of mother and baby homes in Ireland regarding trials that took place between 1934 and 1973 in response to the issues raised ...
gsk

GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen

GSK plc (LSE/NYSE: GSK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that they have reached an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, ...